Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Finland
Sweden
Denmark
Norway
Latest
Trending
Followed

Oncopeptides, Audiocast with teleconference, Q2'24

By Inderes8/14/2024, 7:00 AM
Oncopeptides

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Unknown 1
00:00 - 00:00

Head.

Sofia Heigis
00:01 - 05:35

Welcome to this presentation of our report for the second quarter of 2024. This is our standard disclaimer. With me, I have Henrik Bergentoft who will give a financial update. I will then come back with an update on our European commercialization process and our next step value drivers. But first, starting off with some key highlights. I am happy to announce that the revenue for the second quarter increased from 5.1 million SEK to 7.2 million SEK. This is an increase of 60% compared to the first quarter, as June was our best month on record. I expect this trajectory to continue into Q3 and beyond. Capacity has been available in Spain since May the 1st, and during the same month, we announced the first sale of the drug. The early interest and impact from Spanish doctors confirm that the positive clinical experience from our clinical trials is supporting the understanding of how Pepaxti can help patients. I look forward to seeing sales pick up once we have fully secured regional access in the second half of this year. We have progressed our market access efforts in France by submitting a dossier, and in parallel, the market access work continues in other markets. I will revert to our European plan and provide more details shortly. During the second quarter, we announced that the first drug candidate based on the company's unique small polypeptide-based innate killer indicators on the SPiKE platform has been selected, as well as the inclusion of the first patient in our German real-world study aimed at generating important data in Germany, which will support the understanding of how real-world patients are treated and what difference Pepaxti can make for these patients. Finally, I want to mention that we recently expanded our World Orphan Drug Alliance partnership by signing an agreement with World Pharma and Bihar for named patient sales in Africa with a focus on South Africa. I will talk a bit more about that soon, but before then, let us focus on the financials. Germany is our first launch market and a major contributor to first-year growth in sales of Pepaxti. This graph shows the growth up until the end of Q2, with an increase in sales by double-digit percentages quarter over quarter starting from low levels. It requires hard work. But what we all expect to continue over time is, however, not given in a crowded market like the Multiple Myeloma market, not least in Germany, where physicians have access to all drugs either through commercial or clinical trials, sales data that we obtained confirms that some of our competitors are struggling to grow at all, which makes our growth encouraging and is clearly based on that. We are focused on a different patient population with a different product, bringing value to patients. We still have a long way to go to achieve profitability in 2026, but I am happy to remain on track. We continue to focus on penetrating the scattered German market, where the key to success is to generate a positive clinical experience, which we have been doing, and are focused on continuing to do. We do not only get positive feedback from physicians, but the fact that close to 70% of patients are getting a second cycle demonstrates the value of Pepaxti, and in addition, the number of patients going on three cycles or more has doubled between the two quarters. Regarding customers, we are encouraged to see that we have a good mix of new customers ordering as well as old customers returning. It's also important to note that we have doubled the number of vials ordered by University Hospitals in the second quarter versus the first quarter. This is a sign of the increased collaboration support that we need in Germany, as colleagues do need experience to be able to recommend Pepaxti to office-based physicians. We have a large and promising market in Spain, where we have now recruited a full team, and we are working to secure regional access. I'm happy to share that we are tracking according to our plans. Pepaxti is well positioned in the patient population that is dominating the real-world study, which includes elderly and more difficult to treat patients. Due to this, recruiting the first patient in our inaugural study focused on our target population marks a significant milestone for us. Harbor is the name of the real-world study in Germany, and soon we will initiate a sister study, Lagoon, in Spain. Our aim is to capture the real-world experiences across all major markets to support our journey to profitability by 2026. Of course, we need to add sales from more markets, which I will discuss in detail shortly. With that, I would like to hand over to Henrik for a financial update.

Henrik Bergentoft
05:37 - 08:59

Thank you so much, Sofia. Starting off with an overview of the profit and loss statement for the second quarter compared to the same period last year. I want to highlight in regards to sales that last year included a reversal of a return reserve. For the second quarter of 2023, underlying sales amounted to $1.9 million, compared to $8.2 million for the second quarter of 2024. That said, I want to draw your attention to both total underlying sales and total costs. Both metrics are pointing in the right direction, indicating a significant increase in underlying sales compared to last year and also the first quarter of this year. We're achieving this with cost control, as evidenced by lower total costs compared to last year. In summary, this quarter effectively encapsulates our strategic plan focused on sales growth coupled with cost control. Moving to the next slide, we will take a closer look at our operating expenses. Our research and development costs were 28 million, in fact, compared to 38 million last year. There are currently no clinical studies ongoing with the phase three study. The phase three study, Ocean, was completed during the third quarter of 2023. Also, during the third quarter of 2023, refunds totaling 44 million SEK were received for final settlements of completed studies, which positively influenced the costs. There won't be corresponding refunds during 2024 as these were one-time recoveries. Our marketing and sales costs increased to 36 million, compared to 33 million during the same quarter last year. The increased cost relates to our ongoing commercialization efforts in Europe, which Sofia will elaborate on in more detail in the presentation. Our administrative costs highlight our cost control ambitions, showing a decrease from last year's 19 million to 16 million this quarter. Moving on to the next slide, let's take a look at our liquidity position. Our cash position at the end of the second quarter was 383 million SEK, up from 178 million at the end of 2023, and 105 million at the end of the first quarter this year. I would like to point out that our cash position includes a positive timing effect of incoming and outgoing VAT payments of 105 million SEK, with a corresponding negative effect anticipated in the upcoming third quarter. The rights issue, completed in May, net of the rights issue costs, infused 270 million SEK into our liquidity position. And as Sofia mentioned, our current liquidity position is estimated to sustain us until we reach cash flow positivity by the end of 2026. And with that, back to you, Sofia.

Sofia Heigis
09:00 - 15:27

Thank you, Henrik. I will now provide an update on our European commercialization strategy, followed by an overview of our next steps. Value drivers include geographic expansion for Pepaxti to the rest of the world and our pipeline progress. We have attracted many new shareholders following our rights issue, which is why I wish to reiterate some fundamental facts about our European commercialization strategy. It is grounded on Pepaxti being a fully approved drug for treating an incurable disease, providing an expanding market opportunity valued at 1.5 billion SEK. Currently, our focus is on increasing sales in markets where we have secured access, diversifying our revenue streams by opening new markets, and forming partnerships for our geographic expansion. These efforts are now fully financed, enabling us to achieve our profitability target by the end of 2026. A short reminder of our business model, which is designed to allow for maximum cost-effectiveness, providing high returns due to high margins and low cost of sold goods. Now let's take a look at our launch progress in Europe. Our ambition remains to launch as fast as possible, with a price that reflects our innovation and provides value to both patients and shareholders. In our profitability plan, we have counted on sales from Germany, Austria, Spain, Italy, the Netherlands, and some in the Nordics. These are the different steps in the market access process, and let me remind you of that. The timelines for the review and negotiation phases are country-specific and are largely controlled by payers. Our last quarterly update was held relatively recently, and due to our belated Q1 report, we have since encountered holiday periods in Europe. We have continued our dialogue with payers in Ireland, Norway, and Italy. We have one major development to report, which is that we have submitted a value dossier in France that is currently being reviewed by the payer. This review will conclude the cost-effectiveness and benefit assessment and takes approximately six months. France is in our third launch phase due to how difficult it is to gain a reasonable price in France, but given the size and potential of the market, and given the support and feedback we have gained from key experts on the unmet need for our medicine, we will do all we can to give French patients access to Pepaxti. As France is not part of our profitability plan, unlocking France ahead of 2026 would be an upside. In addition to Germany and Spain, the largest markets where we are currently selling, we also see sales in Greece and Austria, which is following the logic of other markets. Key opinion leader support and positive clinical experiences are generating demand as the multiple myeloma treatment landscape is rapidly evolving. In particular, more immunotherapies are being launched, focusing on earlier lines of treatment, which are starting to become crowded. Just recently, one big pharma company announced that they are shutting down the development of their bispecific for multiple myeloma, which is a sign that the competition in this space is fierce. Unmet medical need in later lines for other modes of action, however, remains due to immune exhaustion, which increases with successful treatments in earlier lines. The patient population in later lines is growing, and Pepaxti with its unique mode of action can take a strong position and make a big difference for these patients. Before we move to questions and answers, I would also like to talk about our next steps as value drivers. And we have some exciting developments both on our partnership side as well as pipeline progress. As I mentioned in the introduction, we have just recently signed an agreement with a World Orphan Drug Alliance partner covering Africa. This is a partner that is an expert in named patient sales in rare diseases and very well connected within the multiple myeloma community. Through our partnership with Red Pharma in Bihar, we have the potential to, on request, sell to Pakistan and the entire sub-Saharan Africa. But the focus and potential is in South Africa. We are working with named patient sales partnerships for a couple of reasons. First, we can expect to reach patients and see sales between 6 to 12 months. This may sound long, but it's far shorter than if we were to go for regulatory approval and regular market access. Secondly, the nature of named patient sales will tell us if it's worthwhile to invest in further commercialization, letting us test the market through these partnerships without jeopardizing our focus from our core revenue stream, which is Europe. In markets where we believe in a good return on investment to immediately go for regulatory approval, we are exploring other types of partnerships, and during the second quarter, we have advanced our discussions with partners and regulators in additional markets focusing on Japan, China, and South Korea, which we believe remain the most promising. And we hope to be able to share news on progress in some of those in the near future. Let me spend some time on our pipeline. As you know, we have two technology platforms: the SPiKE platform and the PDC platform. During the second quarter, we selected our first candidate drug, or SP1, from the SPiKE platform, which I wish to focus on now. Before I speak more about our construct, let's have a brief look at how natural killer cell engagement can differ from T cell therapy. Immunotherapy means that we are utilizing the immune system to fight cancer, and T cell therapies, clinically proven and launched across many different tumor types, are known to be very effective. But with the challenge and risk of severe side effects that need to be carefully monitored and managed. To put it simply, this is due to two powerful T cells.

Unknown 1
15:27 - 15:30

Activation in.

Sofia Heigis
15:30 - 18:29

CAR T-cell therapy is not yet clinically proven, and natural killer cells are part of the immune system that are less easy to activate, which is also why there are mixed opinions. If engagement will work as a therapeutic approach. What everyone agrees on is that if we manage to develop a drug with similar anti-tumor activity, it will be just as effective as T cell therapy. That medicine will most likely be better tolerated and easier to manage, which would be a huge patient and medical system benefit. The SPiKE platform and PDC drugs have the unique property of being small constructs, as they're built on antibody technology. As you can see on this slide, it's a fraction of the size of an antibody. So why is that good? Well, we get the short distance between the SPiKE binding interface and their targets, which puts the natural killer cell in close contact with the tumor cell. This should be an advantage over antibodies as proximity increases avidity, which translates into activity. Furthermore, it allows better tissue distribution, benefiting solid tumor applicability, which has been seen to be a barrier with NK cells. We also see extensive tissue distribution, which is an advantage over antibodies and enables pharmacokinetic properties that allow the immune systems to rest, counteracting immune exhaustion, which is common and problematic with T cell therapy. Today, we have demonstrated efficacy in the pre-clinical setting, and having chosen our first candidate drug, we will continue to advance our efforts with SP1 in the pre-clinical phase towards clinical trials, at which point we will be able to move forward into the clinic. It depends on a few factors, including the time it takes to complete the preclinical work, which encompasses toxicology studies and further chemistry, manufacturing, and control tasks on SPiKE. In addition, we need to secure financing for the first clinical study, which is not part of our current financial plan, and we are looking into different options, including partnerships. This is a prioritized area for us and we will keep you informed as our plans are advancing. We are truly excited to progress our pipeline for the future. Our major focus as an organization here and now is, however, our European commercialization efforts, which will drive us towards becoming a profitable company by the end of 2026. And with that, I would like to say thank you to everyone for listening and hand over to the moderator for any questions. If you wish to.

Operator
18:29 - 18:52

If you have a question, please dial the pound key followed by five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key six on your telephone keypad. The next question comes from Richard Romanus from Redeye. Please go ahead.

Unknown 2
18:56 - 19:22

Good morning. I have a few questions. Let's start with the sales growth, which was obviously quite good at 60%. Is that due to pent-up demand from the flu season, since you had flat sales growth between Q4 and Q1? Could that be because some patients waited?

Sofia Heigis
19:24 - 19:51

Thank you, morning, Richard, and good morning. It's difficult to speculate on exactly where it comes from. But if we look at the overall market that we could see declines slightly in Q1, as we reported, and then stayed flat, we can see that we are growing more than the overall market in the second quarter. So, I would argue it is a true positive trend.

Unknown 2
19:53 - 19:58

And I would assume that the large majority of that growth is from Germany.

Unknown 1
19:58 - 19:59

Yes.

Sofia Heigis
20:00 - 20:01

Correct.

Unknown 2
20:02 - 20:12

Could you say something about how many cycles are typically given to a patient since you treated a few?

Sofia Heigis
20:12 - 21:52

So, if we go back to the basics around our treatment, so everyone understands the logic, the capacity is given once a month. And the average number of treatment cycles is around 4 to 5 in our clinical studies, as we have been fairly recently on the market. Looking at the uptake in Germany, it's too early to give an average for all patients. But the number I mentioned in the webcast just now, which I would like to repeat, is encouraging: around 70% of all patients are continuing to a second cycle. So what does that mean? Well, that means that the patients and the physicians believe that they should continue on treatment, and that it's not immediately a failed treatment, which can definitely happen in such a severe and ill patient population. So that, we believe, is encouraging. If we look at the trend between the two quarters, we can see that we have doubled the number of patients that are continuing on three cycles or more. And what I can share is that one of our very early patients has responded very well and is now continuing on an assumed 15th cycle. So just as in our clinical trials, there is a wide span, and I think it's too early to give an overall average, given that we have, so to say, started to treat many patients only during this quarter. And they have not had the chance to see through the full treatment.

Unknown 2
21:53 - 22:03

Okay, and which do you think would be the next market to be activated after Spain? Would that be Italy?

Sofia Heigis
22:04 - 22:41

As I showed in our market access plan, we have a few countries that we are discussing with payers currently. And that is, to your point, Italy, Ireland, Norway, and the Netherlands. And again, I would like to emphasize that it's not us controlling the timelines, but it's largely the payers controlling the timeline. So, I would like to refrain from commenting on that. But it is basically those markets that we are counting on launching in our profitability plan.

Unknown 2
22:42 - 22:55

Okay. Okay. Um, last, um, last question, question for you to then have some, uh, economic or financial questions. Um, when will SPiKE be ready for a clinical trial?

Sofia Heigis
22:56 - 23:47

Yeah. So just as I said, SPiKE still has some preclinical work to be done, both in terms of tox studies and as well as CMC work. Uh, and, um, looking at that plan, um, it's always difficult to say exactly when you can enter the clinic, but I think it's fair to say that if we move with speed on that plan, you can see the clinic within a couple of years. Having said that, I would like to emphasize that in our current financial plan, we have not included any clinical trials. And that is why we are also looking into different opportunities of how to finance such a trial. So we would like to come back with more specifics later on to that question when we have a clearer plan.

Unknown 2
23:48 - 24:10

Great. Um, then, uh, to the financial questions, um, predicted to be cash flow neutral or to make a profit by the end of 2026, and your current cash position should support that, is that with or without the EIB tranches?

Henrik Bergentoft
24:13 - 24:20

Excluding any additional EIB tranches. So any of that would come on top of our current liquidity plan.

Unknown 2
24:24 - 24:47

Uh, okay. And, uh, uh, this is my last question. I noticed you had a quite large increase in non-current assets of around 500 million SEK, which was also the same increase, uh, more or less in equity. What's that? Is that a tax liability?

Henrik Bergentoft
24:48 - 25:21

I think you're referring to the parent company, uh, balance sheet, because that's where you see the increase and that restructuring of our patent portfolio that we have done internally. So basically, uh, moving our patent portfolio from the parent company to a fully owned subsidiary on an arm's length basis. So that is something that's a transaction that only affects the parent company and doesn't, you know, affect the group's financial position or profit and loss statement by any means.

Unknown 2
25:22 - 25:25

Okay. Okay. Perfect. Thanks. Those were all the questions for me.

Sofia Heigis
25:26 - 25:27

Thank you so much.

Operator
25:34 - 25:40

The next question comes from Patrick Lin from DNB markets. Please go ahead.

Unknown 3
25:41 - 26:02

Good morning and thank you. Thank you for taking my question. Just to follow up on the last one there. I mean, Henrik, you mentioned the 105 million in positive cash flow effect from these patents. Move. Uh, just so I understand it correctly, we should expect a -105 million in Q3 on the group cash flow.

Unknown 4
26:02 - 26:05

Yes, that is, uh. That is.

Henrik Bergentoft
26:05 - 26:06

Correct. Yes.

Unknown 3
26:07 - 26:20

So with that, I mean, with the cash of 383 that you had at the end of the quarter, if you adjust for that, that you know will be coming in Q3, the adjusted cash at the end of Q2 would be 278.

Henrik Bergentoft
26:21 - 26:21

That is correct.

Unknown 3
26:22 - 26:56

Okay, good. I just wanted to make sure. Um, then a question to Sophia. I mean, you talk about June being the best month for the company and that you see acceleration and so on. I mean, could you give us a little bit of a flavor of how large the differences between April, May, and June have been and what we should see as, sort of a 60%, quarter over quarter growth. Is that realistic for Q3 as well, or could it even be more so?

Sofia Heigis
26:56 - 28:47

I hesitate to comment on monthly sales and compare the different months. Due to the simple fact that the drug is administered once a month, and with this severe patient population, you can also see delays. That's why I think it's more sound to look at the quarters and compare the different quarters, but obviously, it is. So with the repetitive treatment when you onboard new patients. And given that we see, I would say, such good clinical experience where the large majority of patients are continuing every month when we step up and you're right that I said June is the best month on record so far. We, of course, see an acceleration for the next quarter and the magnitude of the growth, on a quarterly basis, I don't want to comment on, but we do see a clear positive trend in the activity and field. We get more and more support, just as I said that we even unlock university hospitals in Germany, which is difficult, is a sign of that. The colleagues who actually do have a lot of different options, including clinical trials for their patients, really want to gain the experience to be able to recommend the treatment in the office-based setting. And this is what we have been working really, really hard for, as when we started off in Germany, it was a bit of a blank paper as we have been discussing. So, all signs from Germany are positive. And then, obviously, looking into the future, we will also have Spain as a stronger addition and supporter based on the interest we see there.

Unknown 3
28:48 - 29:11

And when you think about the markets where you will sell the product during the second half of this year, are there any of the additional markets that you mentioned to in one of the previous questions that could potentially be added to the sales mix during the second half of this year, or is it primarily Germany and Spain that we should focus on?

Sofia Heigis
29:11 - 29:47

It always takes even when you have negotiated the price, it always takes a couple of months to get sales going. So it will be primarily Germany, Spain, and then of course Austria, and Greece. But having said that, back to my previous message. It's payers controlling the timeline. We are progressing, we're having intense discussions and it's not impossible that we could onboard another market already this year. But we should count on more market supporting significantly more during 2025.

Unknown 3
29:49 - 30:17

Okay, great. And then the last question, I mean, Henrik, you talked about sales growth with cost control. I mean, when we look at the operating spend level that you had in Q2, is that a good proxy for how it will look going forward, or should we expect, for example, sales and marketing spend to continue to increase? And R&D may be as well, given the activities that you have on the SPiKE platform.

Henrik Bergentoft
30:19 - 30:56

Well, thanks for that question. If I may comment separately. You should expect that R&D costs will be more or less at the same level, but again, pointing out that in Q3, the comparison numbers from last year will include this major reversal. So reported numbers will seem like a big increase. But underlying this, we will more or less be in line. Sales and marketing costs will continue to moderately increase to support our commercialization activities. With regards to our administrative costs, you can expect us to be more or less in line. But we are, as of today.

Unknown 3
30:57 - 31:01

Great. Thank you, guys. That's all for me. Thank you.

Sofia Heigis
31:01 - 31:03

Thank you so much, Patrick.

Operator
31:08 - 31:28

As a reminder, if you wish to ask a question, dial pound key five on your telephone keypad. The next question comes from Suzanne Van Vast from VLC. Please go ahead.

Susanne Van Vast
31:32 - 32:26

Hi Tim, this is Suzanne. Thanks for taking my questions. It is good to see the uptick in sales, but allow me to start off with a clarifying question regarding your Pepaxti's guidance. Maybe I missed it in earlier updates, but did the previous range of 7.5 to 200 million change subtly to now at least 1.5 billion? And if that's the case, why is this change? And secondly, your profitability stability guidance includes a 400 million SEK sales level, so that it gives an idea of operating expenses in 2026. But what additional investments do you expect are needed in terms of sales and marketing and R&D, to be able to reach your peak sales guidance? And maybe I have a follow up thereafter.

Sofia Heigis
32:27 - 34:19

Thank you so much, Susanne. So let me start with the question on the market potential, and I'm sorry if I was not clear. There is no change to the market potential. It stays at 1.5 billion SEK for the European market. And when it comes to the profitability guidance, you are, of course, right that it then reflects the cost base. If we comment and if I may repeat what Henrik said, as we unlock more countries, we will, of course, add the local resources needed to those countries. We are, however, operating with a model where we do have all the synergetic resources hired in Stockholm into the headquarters. And there we have a very good foundation set already. So from sales and marketing, it's primarily the kind of launch activity cost as well as the building of the teams in then markets such as Italy. Uh, that will cost because we already have the few full-time employees (FTEs) needed in the Nordics and the Netherlands. Um, so that's on the sales and marketing side. On the R&D side, the R&D costs, uh, we should maybe clarify that, um, under the line of R&D, we of course have pure R&D where we are progressing with the preclinical work for OPS V1. As we said, the SPiKE platform, uh, and in addition, we have what one can argue are R&D resources supporting the commercialization in Europe such as regulatory, pharmacovigilance, quality, all of those resources that you need to have to maintain your license to operate are also under R&D and that cost base will not increase.

Susanne Van Vast
34:21 - 34:50

Got it. Perfect. And then um, my follow-up relates to the US. I appreciate your focus on European commercialization, but I do wonder about the US, uh, after the last news updates in which the FDA confirmed the decision to withdraw. Um, it was mentioned that Oncopeptides would assess the decision. Can you elaborate here? What is there to assess and what options will you be considering? Uh, as a next step, if any. Thank you.

Sofia Heigis
34:51 - 35:40

So when it comes to the US, we have communicated before. Uh, looking at the market, we do believe there is an unmet need for a PDC. Uh, what we are assessing to your point is, uh, which of our PDCs is suitable for that market and how we would go about developing a PDC for the US market, most likely in partnership. But we have left no options untouched. And we have not decided yet exactly how to go about it. But this is a discussion that is ongoing between the management and the board. Uh, when we are looking at our pipeline assets and how we're going to, uh, secure value from the pipeline.

Susanne Van Vast
35:42 - 35:43

Got it. Thank you so much.

Operator
35:50 - 35:58

There are no more questions at this time. So I hand the conference back to the speakers for written questions and any closing comments.

Unknown 4
35:59 - 36:09

Thank you. Uh, we have one or two written questions. One, I think you covered during the conference, but maybe add a couple of more words. How is Asia going?

Sofia Heigis
36:10 - 36:49

So as I mentioned on the call, we are negotiating to end the partnerships for Japan, China, and South Korea currently. And we are, of course, looking at different options but primarily focused on licensing deals. Uh, we are in dialogue with regulatory authorities, primarily in Japan. And, uh, the short answer is that we are progressing well, I would argue, and we will, of course, keep the market posted. Should we hit any specific milestones as part of that process?

Unknown 4
36:50 - 36:58

Another question received over email. Uh, your view on the ownership following the rights issue and the changes that occurred over the summer?

Unknown 1
36:59 - 36:59

Yes.

Sofia Heigis
36:59 - 38:03

Thank you. We have a strong ownership with healthcare sectors that were supportive during the rights issue, as well as Red Mile and Industry Fund, who have been long-time owners in the field of peptides. They have a quite different focus as they are more focused on early-stage biotechs in the preclinical phase. And that is why they refrained from investing in the rights issue. However, they still supported the process through the Industry Fund and consequently decided to sell their shares in peptides. But we do believe we have large, qualitative owners who are highly supportive and engaged, and, of course, we are also happy for all the new investors and owners that decided to join us during the rights issue. So, we believe we do have solid ownership from our perspective.

Unknown 4
38:03 - 38:09

And the question also included the rationale from the Industry Fund and why they decided to exit.

Sofia Heigis
38:09 - 38:35

Yes, so in the fund and what they told us is that they are more focused on early startups in the preclinical phase. They are rarely active or invest in listed companies such as peptides; and peptides are basically no longer a good fit for their investment strategy based on our development.

Unknown 4
38:36 - 38:54

And I think, last but not least, there was an article published in the Blood Cancer Journal, and a question around that was our view on it. So I think maybe a couple of words on what article the question is referring to. And also then, shortly on our view on it.

Sofia Heigis
38:54 - 40:25

Yes, there is a review article, authored by a quite prominent group of myeloma experts, that was published in the Blood Cancer Journal. The title of that article is ‘Progression-Free Survival as a Surrogate Endpoint in Myeloma Clinical Trials: An Evolving Paradigm’. And to put it shortly, I think it's a solid analysis of the data in multiple myeloma clinical trials. I mean, Multiple Myeloma is a very heterogeneous disease. And it requires that the studies are designed with that in mind, as well as analyzed and interpreted by regulatory authorities, companies, and payers with that lens on. So, to conclude, I think it's a very interesting, well-written article. I'm happy to see that this group of experts is essentially concluding the same type of analysis that we did when we analyzed the Ocean trial. And I think it's an interesting discussion and debate because at the end of the day, we all want the same thing. We want to ensure that patients get effective and safe medicines. And that, of course, a subgroup of patients can be considered when that is accurate to do.

Unknown 1
40:25 - 40:26

So.

Unknown 4
40:27 - 40:30

That's the questions we have. So any final remarks.

Sofia Heigis
40:31 - 40:52

No, I would like to thank everyone for listening. Again, I would like to thank everyone for the questions. As always, we are here. Should you have any questions after the presentation, please feel free to contact David. And I would like to wish you all a nice day.

Continue to the webcast
Revenio Group Oyj, Q3'26
Language: English11/12/2026, 1:00 PM
Jukka Kainulainen Good afternoon, and welcome to the Revenio Group Corporation Q3 Earnings Call. My name is Jouni Toijala. I am the CEO. And then, again today we have Jukka Kainulainen, our CFO, on th…
Kamux, Q3'26
Language: English11/12/2026, 9:00 AM
Katerina Heterant Good morning. Welcome to the Kamux Q3 results presentation. My name is Katerina Heterant and I am Head of Investor Relations at Kamux. Today we shall go through the Q3 results presen…
Koskisen, Webcast, Q3'26
Language: Finnish11/12/2026, 8:00 AM
Jukka Pahta Hyvää huomenta ja tervetuloa tähän osavuosikatsaustilaisuuteen! Koskisen tammi–syyskuun osavuosikatsaustilaisuuteen lähdetään otsikolla: Koskisen liikevaihdon kasvu jatkui. Kohonneet kusta…
Reaktor, Q3'26
Language: Finnish11/11/2026, 9:00 AM
Pekka Horo Oikein hyvää aamupäivää kaikille ja tervetuloa tähän meidän webcastiimme. Olen Pekka Horo, Reaktorin toimitusjohtaja, ja kanssani täällä on tänään Antti Akkanen, joka aloitti lokakuussa Rea…
Savox, Q3'26
Language: English11/10/2026, 11:00 AM
Paulina Tanila Our speakers today are CEO Jerry Kettunen and CFO Juha Järvi. Jerry will give an overview of Savox as a company and go through the highlights of the quarter. After that, Juha will conti…
Raisio Oyj, Webcast, Q3'26
Language: Finnish11/10/2026, 10:00 AM
Elli Siltala Hyvää marraskuista päivää Raisiosta! Ja tervetuloa Raision tammi-syyskuun 2026 osavuosikatsauksen webcastiin! Pahoittelut pienistä teknisistä haasteista, mitä meillä oli tässä alussa. Min…
Mandatum Oyj, Audiocast, Q3'26
Language: English11/10/2026, 9:00 AM
Lotta Borgström Good morning, everyone, and welcome to the Mandatum Q3 2026 audiocast. My name is Lotta Borgström from Investor Relations. Joining me today are our CEO, Petri Niemisvirta, and our CFO,…
Solar foods Go-to-market Update
Language: English11/9/2026, 12:00 PM
Maria Hello everyone, and welcome to the Solar Foods go-to-market update. My name is Maria and I'm here today with our CEO, Rami Jokela, and CFO and Deputy CEO, Ilkka Saura. Also with us today is Heli…
Outokumpu, Webcast, Q3'26
Language: English11/6/2026, 12:30 PM
Johan Welcome to the third quarter results webcast. I am responsible for investor relations. We will start with the presentation from our CEO, Kati ter Horst, and our CFO, Marc-Simon Schaar. After the…
Endomines, Webcast, Q3'26
Language: English11/5/2026, 1:00 PM
Andy Turpin Hello, everyone, and welcome to Endomines' third-quarter results webcast. Thanks for joining us today. My name is Andy Turpin and I am the Chief Communications Officer here at Endomines. A…
Lemonsoft Oyj, Q3'26 webcast
Language: English11/5/2026, 11:00 AM
Unknown 1 Welcome to the Lemonsoft Q3 results presentation. We will start with the presentation from CEO Alpo Luostarinen, followed by the Q&A. You can send your questions throughout the event via the…
Enersense, Webcast, Q3'26
Language: English11/5/2026, 10:30 AM
Liisa Tamminen Hello and welcome to the Enersense Q3 2026 results webcast. My name is Liisa Tamminen from Enersense Investor Relations. And with me here I have our CEO, Kari Sundbäck, and CFO, Jan-Elo…
Sitowise, Q3'26
Language: English11/5/2026, 10:00 AM
Mari Reponen Good day everyone, and welcome to the Sitowise Q3 2026 results audiocast. My name is Mari Reponen, and I am responsible for strategy and IR here at Sitowise. And today with me are our act…
Orthex, Webcast, Q3'26
Language: English11/5/2026, 9:00 AM
Alexander Rosenlew Good morning and welcome to the Orthex Interim Report. My name is Alexander Rosenlew and with me I have Saara Mäkelä, CFO, and Hanna Kukkonen, our CMSO. We will take you through the…
Suominen Oyj, Q3'26
Language: English11/5/2026, 8:30 AM
Anni Luoma Good morning, everyone, and welcome to the Suominen Q3 webcast. My name is Anni Luoma. I am the Manager of External Communications and Investor Relations at Suominen. Here with me are our P…
Lumo, Webcast, Q3'26
Language: English11/5/2026, 8:00 AM
Niina Saarto Good morning, all. Welcome. This is Lumo Homes plc's third quarter result webcast. I am Niina Saarto from Treasury and Investor Relations. Today I have two gentlemen here with me, namely…
CapMan, Webcast, Q3'26
Language: English11/5/2026, 7:30 AM
Charlotte Good morning and welcome to this presentation of CapMan. Q3 2026 interim report. Presenting today we have Pia Kåll, CEO of CapMan. And after the presentation, we will have a Q&A session. You…
Marimekko, Webcast, Q3'26
Language: English11/4/2026, 12:00 PM
Anna Good afternoon. My name is Anna and I am the IRO of Marimekko. It is my pleasure to welcome you to our Q3 webcast. With me, I have our president and CEO, Tiina Alahuhta, who will walk you through…
Administer, Webcast, Q3'26
Language: Finnish11/4/2026, 9:00 AM
Kimmo Herranen Welcome to the Administer Q3 2026 interim report. Results. Meillä on se alkaa. I am Kimmo Herranen. Kalle Lehtonen. Also. Kaarina og. Yelken. Kalle Lehtonen En el coco. Madan. Parannus.…
Kempower, Webcast, Q3'26
Language: English11/4/2026, 8:30 AM
Unknown 1 Powering the planet. Kempower. We charge our planet for the better. By powering the electric movement. We enable quick and scalable EV charging solutions for everyone and everywhere. We ma…